Rapid Dose Therapeutics Announces Nutraceutical Reseller Agreement for Canada, United States and India
February 27 2020 - 7:00AM
Rapid Dose Therapeutics Corp. (
CSE:
DOSE) (“
RDT” or the
“
Corporation”) is pleased to announce an Agreement
with Perennial Brands, a DCM company, for the distribution and sale
of nutraceutical oral dissolvable strip products in Canada, the
United States and India for a period of three years.
RDT will benefit from Perennial’s established
global expertise in branding, marketing and distribution of
consumer packaged goods (CPG) in the North American markets,
combined with its strategic relationships in the fast-growing
Indian market, and the backing of DCM, a North American leader in
marketing services.
“Our passion is building great brands that
flourish because of gaps left in the market by risk-averse
corporate giants,” said Chris Lund, Chief Innovation Officer, DCM.
“We believe the RDT QuickStrip™ is filling just such a gap, and we
look forward to seeing it succeed by applying measured doses of
inspired innovation, battle-tested commercial capabilities, and a
reliable source of funding.”
“RDT is excited to continue to offer QuickStrip™
nutraceutical product formulations that are Quick, Convenient,
Precise, and Discreet™ to Canadian, US and Indian audiences,” said
Mark Upsdell, CEO, Rapid Dose Therapeutics. “This Agreement will
continue to strengthen and accelerate our objective to deliver a
consistent, premium, consumer-focused health and wellness product
to global markets.”
About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a publicly
traded Canadian life sciences company that provides innovative,
proprietary drug delivery technologies designed to improve outcomes
and quality of lives. RDT offers Quick, Convenient, Precise and
Discreet™ choices to consumers. RDT is focused and committed to
clinical research and product development for the healthcare
manufacturing industry, including nutraceutical, pharmaceutical and
cannabis industries. Within the cannabis sector, RDT provides a
turn-key business solution which enables RDT’s QuickStrip™
proprietary drug delivery technology to be licensed by select
partners. RDT’s service-based annuity contracts drive recurring
revenue which enables rapid expansion into emerging markets —
generating value for consumers and shareholders. RDT is committed
to continually create innovative solutions aimed at multiple
consumer segments and future market needs — including humans,
animals and plants.
For more information, visit:
www.rapid-dose.com.
For further inquiries please contact:
Kristina SheaSVP, Marketing &
CommunicationsCorporate Secretarykshea@rapid-dose.com(905)
876-8003
Social
MediaRapidDoseTherapeutics.linkedinRapidDoseTherapeutics.twitterRapidDoseTherapeutics.facebookQuickStrip.instagram
Any statements that are contained in this news
release that are not statements of historical fact may be deemed to
be forward-looking statements. Forward-looking statements are often
identified by terms such as “may”, “should”, “anticipate”,
“expect”, “potential”, “believe”, “intend”, “will”, “could”, “are
planned to”, “are expected to” or the negative of these terms and
similar expressions. Statements containing forward-looking
information, including, without limitation, in respect of the
Corporation securing particular forms of insurance coverage and
certain directors and officers rejoining the Corporation in
particular roles express, as at the date of this news release, the
plans, estimates, forecasts, projections, expectations or beliefs
of RDT management as to future events or results and are believed
to be reasonable based on information currently available to RDT
management. Forward-looking statements necessarily involve known
and unknown risks, including, without limitation, risks associated
with general economic conditions; adverse industry events; the
ability to implement its business strategies; competition; and
other risks. Readers are cautioned that the foregoing list is
not exhaustive. There can be no assurance that statements of
forward-looking information, although considered reasonable by RDT
management at the time of preparation, will prove to be accurate as
there can be no assurance that the plans, intentions or
expectations upon which they are based will occur. Actual results
and future events could differ materially from those anticipated in
such forward-looking statements. Readers should not place undue
reliance on forward-looking statements. Forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement.
The Canadian Securities Exchange has not
reviewed and does not accept responsibility for the adequacy or
accuracy of the content of this news release.
Rapid Dose Therapeutics (CSE:DOSE)
Historical Stock Chart
From Oct 2024 to Nov 2024
Rapid Dose Therapeutics (CSE:DOSE)
Historical Stock Chart
From Nov 2023 to Nov 2024